Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
NRXP Stock Chart & Stats
$2.24
-$0.69(-14.70%)
At close: 4:00 PM EST
$2.24
-$0.69(-14.70%)
Day’s Range― - ―
52-Week Range$1.15 - $6.01
Previous CloseN/A
Volume2.07M
Average Volume (3M)475.66K
Market Cap
$65.13M
Enterprise Value$65.79M
Total Cash (Recent Filing)$7.18M
Total Debt (Recent Filing)$347.00K
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Mar 26, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding23,769,901
10 Day Avg. Volume509,446
30 Day Avg. Volume475,656
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.00
Price to Sales (P/S)0.00
P/FCF Ratio-2.18
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue271.85
Enterprise Value/Gross Profit456.86
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$32.50Price Target Upside1350.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA SupportThe FDA has waived the filing fee for the NRX-100 NDA and granted it Fast Track Designation, indicating that the agency sees ketamine as a promising approach to treat an unmet need.
Regulatory AdvancementsNRx Pharmaceuticals reaches a point of strategic inflection, characterized by advancement of regulatory applications and transition to a revenue-generating company.
Revenue GenerationThe launch of the Hope Therapeutics clinic network resulted in NRx reporting revenue for the first time of approximately $240,000 following the acquisition of Dura Medical.
Bears Say
Financial PerformanceThe company reported a net loss and operating loss, and while it has added some revenue-generating Hope clinics, the level of revenue generation is below the originally guided $100 million.
Net LossNRXP reported a net loss of $17.6M, primarily from fair value accounting measurements.
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.15 and its highest was $6.01 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $65.13M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Mar 26, 2026 which is in 120 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on Nov 17, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.131 by -$0.139.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is 0.01.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 23,769,901 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.131. Following the earnings report the stock price went down -15.261%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.50 (1350.89% Upside)
$32.50 (1350.89% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.09%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRX Pharmaceuticals (NRXP) is a biopharmaceutical company focused on developing innovative therapies to address unmet needs in the treatment of central nervous system disorders and other critical health conditions. The company operates in the healthcare sector with a particular emphasis on drug development for serious mental illnesses, respiratory diseases, and other critical care indications. Its core products include investigational drugs designed to offer new treatment options for patients with severe mental health disorders and life-threatening pulmonary diseases.
NRXP Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in drug development and clinical progress, along with strong financial positioning and strategic expansions in clinic operations. However, there were challenges such as increased operational losses and limited initial revenue. Despite these challenges, the overall sentiment is optimistic due to the transformative progress and potential for substantial growth.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$32.50
▲(1350.89% Upside)
Technical Analysis
CervoMed
―
Coeptis Therapeutics Holdings
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
15.88% Insiders
2.54% Mutual Funds
10.30% Other Institutional Investors
67.82% Public Companies and Individual Investors